Clinical trial
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT06547216 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
- Lead sponsor
- Avidity Biosciences, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 25, 2024
- Completion date
- June 30, 2030
- Enrollment
- 84 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
atrophies, facioscapulohumeral, atrophy, facioscapulohumeral, dystrophies, facioscapulohumeral muscular, dystrophies, landouzy-dejerine, dystrophy, facioscapulohumeral muscular, dystrophy, landouzy-dejerine, facio-scapulo-humeral dystrophy, facioscapulohumeral atrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, fascioscapulohumeral muscular dystrophy, fascioscapulohumeral muscular dystrophy type 1, fascioscapulohumeral muscular dystrophy type 2, fmd, fmd2, fsh, fsh muscular dystrophy, fshd, fshd1, fshd2, landouzy dejerine dystrophy, landouzy-dejerine muscular dystrophy, landouzy-dejerine syndrome, muscular dystrophies, muscular dystrophy, facioscapulohumeral, muscular dystrophy, landouzy dejerine, progressive muscular dystrophy